(Q34798154)

4 August 2017

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial (English)

1 reference

4 August 2017

phase I clinical trial

0 references

0 references

0 references

Delphine Boche

2

0 references

Ghasem Yadegarfar

object named as

Ghasem Yadegarfar

4

0 references

Clive Holmes

object named as

Clive Holmes

1

0 references

Roy W Jones

7

object named as

Roy W Jones

1 reference

4 August 2017

David Wilkinson

3

1 reference

4 August 2017

Vivienne Hopkins

5

1 reference

4 August 2017

Anthony Bayer

6

1 reference

4 August 2017

Roger Bullock

8

1 reference

4 August 2017

Seth Love

9

1 reference

4 August 2017

James W Neal

10

1 reference

4 August 2017

Elina Zotova

11

1 reference

4 August 2017

James A R Nicoll

12

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

4 August 2017

1 reference

4 August 2017

372

1 reference

4 August 2017

216-223

1 reference

4 August 2017

9634

1 reference

Has the amyloid cascade hypothesis for Alzheimer's disease been proved?

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Abeta species removal after abeta42 immunization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Cerebral hemorrhage after passive anti-Abeta immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Predicting the failure of amyloid-beta vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Good and Bad Amyloid Antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

1 reference

7 January 2021

A new rating scale for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Functional disability in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Alzheimer neuropathologic alterations in aged cognitively normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

A specific amyloid-beta protein assembly in the brain impairs memory

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Immunology and immunotherapy of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961075-2

7 January 2021

10.1016/S0140-6736(08)61075-2

Identifiers

DOI

1 reference

4 August 2017

1 reference